Predicting Lipid-Lowering Medication Persistence after the First Cardiovascular Disease Hospitalization

被引:1
作者
Hu, Feiyu [1 ]
Warren, Jim [1 ]
Exeter, Daniel J. [2 ]
机构
[1] Univ Auckland, Sch Comp Sci, Private Bag 92019, Auckland, New Zealand
[2] Univ Auckland, Sch Populat Hlth, Auckland, New Zealand
关键词
medication persistence; cardiovascular diseases; machine learning; prediction models; ARTIFICIAL NEURAL-NETWORK; CORONARY-HEART-DISEASE; SECONDARY PREVENTION MEDICATIONS; DECISION-SUPPORT-SYSTEM; MYOCARDIAL-INFARCTION; NEW-ZEALAND; LOGISTIC-REGRESSION; STATIN THERAPY; RISK-FACTOR; ADHERENCE;
D O I
10.1055/s-0040-1713905
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
Objectives This study analyzed patient factors in medication persistence after discharge from the first hospitalization for cardiovascular disease (CVD) with the aim of predicting persistence to lipid-lowering therapy for 1 to 2 years Methods A subcohort having a first CVD hospitalization was selected from 313,207 patients for proportional hazard model analysis. Logistic regression, support vector machine, artificial neural networks, and boosted regression tree (BRT) models were used to predict 1- and 2-year medication persistence Results Proportional hazard modeling found significant association of persistence with age, diabetes history, complication and comorbidity level, days stayed in hospital, CVD diagnosis type, in-patient procedures, and being new to therapy. BRT had the best predictive performance with c-statistic of 0.811 (0.799-0.824) for 1-year and 0.793 (0.772-0.814) for 2-year prediction using variables potentially available shortly after discharge. Conclusion The results suggest that development of a machine learning-based clinical decision support tool to focus improvements in secondary prevention of CVD is feasible.
引用
收藏
页码:61 / 74
页数:14
相关论文
共 50 条
  • [21] New Male Users of Lipid-Lowering Drugs for Primary Prevention of Cardiovascular Disease: The Impact of Treatment Persistence on Morbimortality. A Longitudinal Study
    Aguilar-Palacio, Isabel
    Rabanaque, Maria Jose
    Maldonado, Lina
    Chaure, Armando
    Abad-Diez, Jose Maria
    Leon-Latre, Montse
    Casasnovas, Jose Antonio
    Malo, Sara
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, 17 (20) : 1 - 13
  • [22] Lipid-lowering treatment among older patients with atherosclerotic cardiovascular disease
    Nanna, Michael G.
    Nelson, Adam J.
    Haynes, Kevin
    Shambhu, Sonali
    Eapen, Zubin
    Cziraky, Mark J.
    Calvert, Sara B.
    Pagidipati, Neha J.
    Granger, Christopher B.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2023, 71 (04) : 1243 - 1249
  • [23] New Treatment Targets and Innovative Lipid-Lowering Therapies in Very-High-Risk Patients with Cardiovascular Disease
    Burger, Achim Leo
    Pogran, Edita
    Muthspiel, Marie
    Kaufmann, Christoph Clemens
    Jaeger, Bernhard
    Huber, Kurt
    BIOMEDICINES, 2022, 10 (05)
  • [24] Cardiovascular risk and lipid-lowering drug therapy
    Stulnig, T.
    DIABETOLOGE, 2012, 8 (07): : 568 - 572
  • [25] Cardiovascular Pharmacogenetics of Antihypertensive and Lipid-Lowering Therapies
    Vanichakarn, P.
    Hwa, J.
    Stitham, J.
    CURRENT MOLECULAR MEDICINE, 2014, 14 (07) : 849 - 879
  • [26] Niacin: another look at an underutilized lipid-lowering medication
    Creider, Julia C.
    Hegele, Robert A.
    Joy, Tisha R.
    NATURE REVIEWS ENDOCRINOLOGY, 2012, 8 (09) : 517 - 528
  • [27] Lipid-Lowering Therapy after Acute Coronary Syndrome
    Pogran, Edita
    Burger, Achim Leo
    Zweiker, David
    Kaufmann, Christoph Clemens
    Muthspiel, Marie
    Rega-Kaun, Gersina
    Wenkstetten-Holub, Alfa
    Wojta, Johann
    Drexel, Heinz
    Huber, Kurt
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (07)
  • [28] Reasons for Discontinuation of Lipid-Lowering Medications in Patients with Chronic Kidney Disease
    Morrison, Fritha J. R.
    Zhang, Huabing
    Skentzos, Stephen
    Shubina, Maria
    Bentley-Lewis, Rhonda
    Turchin, Alexander
    CARDIORENAL MEDICINE, 2014, 4 (3-4) : 225 - 233
  • [29] Gender Disparities in Lipid-Lowering Therapy in Cardiovascular Disease: Insights from a Managed Care Population
    Rodriguez, Fatima
    Olufade, Temitope O.
    Ramey, Dena R.
    Friedman, Howard S.
    Navaratnam, Prakash
    Heithoff, Kim
    Foody, JoAnne M.
    JOURNAL OF WOMENS HEALTH, 2016, 25 (07) : 697 - 706
  • [30] Systemic and specific effects of antihypertensive and lipid-lowering medication on plasma protein biomarkers for cardiovascular diseases
    Enroth, Stefan
    Maturi, Varun
    Berggrund, Malin
    Enroth, Sofia Bosdotter
    Moustakas, Aristidis
    Johansson, Asa
    Gyllensten, Ulf
    SCIENTIFIC REPORTS, 2018, 8